Source: Annual Congress 2010 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. McCullagh, C. Costello, S. Gaine, P. McLoughlin (Dublin, Ireland). CXCL12 as a potential disease marker for pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 3513

Member's Comments

No comment yet.

Related content which might interest you: Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1 Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 How to detect disease progression in pulmonary arterial hypertension Source: Eur Respir Rev 2012; 21: 40-47 Year: 2012 Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease Source: Eur Respir J, 55 (3) 1900169; 10.1183/13993003.00169-2019 Year: 2020 Determinants and prognostic value of kidney disease in pulmonary arterial hypertension Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 Towards prognostic biomarkers in pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 799-801 Year: 2012 The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Predictive factors of endothelial function in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Prognosis in COPD Year: 2008 Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007 Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 The link between systemic inflammation and pulmonary hypertension in patients with stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 53s Year: 2005 Hepatic function markers in COPD as a systemic implication of the disease Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates Year: 2008 Prognostic value of right ventricular function in patients with severe pulmonary hypertension associated with respiratory disease Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive lung disease? Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016